A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima
View/ Open
Issue Date
2017-04Author
Pisupati, Karthik
Tian, Yuwei
Okbazghi, Solomon Zeray
Benet, Alexander
Ackermann, Rose
Ford, Michael
Saveliev, Sergei
Hosfield, Christopher M.
Urh, Marjeta
Carlson, Eric
Becker, Christopher
Tolbert, Thomas J.
Schwendeman, Steven P.
Routolo, Brandon T.
Schwendeman, Anna
Publisher
American Chemical Society
Type
Article
Article Version
Scholarly/refereed, author accepted manuscript
Rights
Copyright © 2017 American Chemical Society
Metadata
Show full item recordAbstract
In April 2016, the Food and Drug Administration approved the first biosimilar monoclonal antibody (mAb) – Inflectra/Remsima (Celltrion) based off the original product Remicade (infliximab, Janssen). Biosimilars promise significant cost savings for patients, but the unavoidable differences between innovator and copycat biologics raise questions regarding product interchangeability. In this study, Remicade and Remsima were examined by native mass spectrometry, ion mobility and quantitative peptide mapping. The levels of oxidation, deamidation and mutation of individual amino acids were remarkably similar. We found different levels of C-terminal truncation, soluble protein aggregates and glycation that all likely have a limited clinical impact. Importantly, we identified over 25 glycoforms for each product and observed glycoform population differences, with afucosylated glycans accounting for 19.7% of Remicade and 13,2% of Remsima glycoforms, which translated into a 2-fold reduction in FcγRIIIa binding for Remsima. While this difference was acknowledged in Remsima regulatory filings, our glycoform analysis and receptor binding results appear to be somewhat different from the published values, likely due to methodological differences between laboratories and improved glycoform identification by our laboratory using a peptide map-based method. Our mass spectrometry based analysis provides rapid and robust analytical information vital for biosimilar development. We have demonstrated the utility of our multiple attribute monitoring workflow using the model mAbs Remicade and Remsima, and have provided a template for analysis of future mAb biosimilars.
Collections
Citation
Pisupati, K., Tian, Y., Okbazghi, S., Benet, A., Ackermann, R., Ford, M., … Schwendeman, A. (2017). A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. Analytical Chemistry, 89(9), 4838–4846. http://doi.org/10.1021/acs.analchem.6b04436
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.